{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:38:01Z","timestamp":1770827881734,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To elucidate the influence of CXC motif chemokine receptor 4 (CXCR4)\u2013directed imaging on staging and proposed oncologic management in patients with digestive system tumors compared with guideline-appropriate imaging (GAI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From our PET\/CT database, we retrospectively identified 37 patients with advanced digestive system tumors, which had been scheduled for CXCR4-targeted [<jats:sup>68<\/jats:sup>Ga]Ga-pentixafor PET\/CT for potential theranostic considerations. In all subjects, concurrent GAI was also available. Patients were afflicted with gastroenteropancreatic neuroendocrine neoplasms (21\/37 [56.8%]), pancreatic duct adenocarcinoma (6\/37 [16.2%]), cholangiocarcinoma (5\/37 [13.5%]), hepatocellular carcinoma (4\/37 [10.8%]), and colorectal carcinoma (1\/37 [2.7%]). Staging results and impact on proposed oncologic management by a board-certified gastroenterologist were compared between GAI and [<jats:sup>68<\/jats:sup>Ga]Ga-pentixafor PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Relative to GAI, CXCR4-directed PET\/CT resulted in staging changes in 14 of 37 patients (37.8%). Upstaging was seen in 1 of 14 patients (7.1%), whereas downstaging was recorded in the remaining 13 of 14 patients (92.9%). Among those, staging changes would not have triggered any changes in oncological management in 4 of 14 (28.6%). For the remaining 10 of 14 patients (71.4%), however, findings on [<jats:sup>68<\/jats:sup>Ga]Ga-pentixafor PET\/CT would have impacted subsequent clinical algorithm, including the necessity for further diagnostic steps or failure to initiate antitumor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>[<jats:sup>68<\/jats:sup>Ga]Ga-pentixafor PET\/CT missed tumor lesions in 13 patients with digestive system tumors, which would have led to inappropriate downstaging and clinical treatment of 10 patients. As such, our results do not support a more widespread use of [<jats:sup>68<\/jats:sup>Ga]Ga-pentixafor PET\/CT for clinical staging in those tumor entities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004674","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T18:01:23Z","timestamp":1683828083000},"page":"586-593","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Impact of CXCR4-Directed PET\/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors"],"prefix":"10.1097","volume":"48","author":[{"given":"Alexander","family":"Weich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Schl\u00f6telburg","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schirbel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Kosmala","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jacr.2022.02.012","article-title":"ACR Appropriateness Criteria\u00ae staging of colorectal cancer: 2021 update","volume":"19","year":"2022","journal-title":"J Am Coll Radiol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA\u2013conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1016\/j.jacr.2017.08.050","article-title":"ACR Appropriateness Criteria(\u00ae) staging of pancreatic ductal adenocarcinoma","volume":"14","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1038\/s41598-019-39607-2","article-title":"Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"e0130192","DOI":"10.1371\/journal.pone.0130192","article-title":"CXCR4\u2014a prognostic and clinicopathological biomarker for pancreatic ductal adenocarcinoma: a meta-analysis","volume":"10","year":"2015","journal-title":"PloS One"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.bjc.6603251","article-title":"Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4","volume":"95","year":"2006","journal-title":"Br J Cancer"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.3390\/cancers13133284","article-title":"Prognostic significance of CXCR4 in colorectal cancer: an updated meta-analysis and critical appraisal","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of chemokine receptor 4 expression in neuroendocrine tumors\u2014a triple tracer comparative approach","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/diagnostics11040605","article-title":"CXCR4-directed PET\/CT in patients with newly diagnosed neuroendocrine carcinomas","volume":"11","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"bib11-20250621","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-pentixafor PET","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fonc.2019.00770","article-title":"CXCR4-directed imaging in solid tumors","volume":"9","year":"2019","journal-title":"Front Oncol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11307-022-01717-1","article-title":"Impact of tumor burden on Normal organ distribution in patients imaged with CXCR4-targeted [(68)Ga]Ga-pentixafor PET\/CT","volume":"24","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13550-021-00822-6","article-title":"Investigation of spleen CXCR4 expression by [(68)Ga]pentixafor PET in a cohort of 145 solid cancer patients","volume":"11","year":"2021","journal-title":"EJNMMI Res"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/RLU.0000000000004480","article-title":"Impact of 68 Ga-FAPI-04 PET\/CT on staging and therapeutic management in patients with digestive system tumors","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","year":"2023","journal-title":"Ann Oncol"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","year":"2022","journal-title":"J Hepatol"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1245\/s10434-017-5810-x","article-title":"Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a Surveillance, Epidemiology and End Results (SEER) analysis","volume":"24","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.4143\/crt.2019.023","article-title":"Validation of the 8th AJCC Cancer Staging System for pancreas neuroendocrine tumors using Korean nationwide surgery database","volume":"51","year":"2019","journal-title":"Cancer Res Treat"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/030089161009600532","article-title":"The ENETS guidelines: the new TNM classification system","volume":"96","year":"2010","journal-title":"Tumori"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","year":"2020","journal-title":"Histopathology"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers","volume":"25","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.115.161034","article-title":"First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/RLU.0000000000004442","article-title":"Similar findings on 68Ga-pentixafor PET\/CT and 18F-FDG PET\/CT in a patient with widespread metastatic hepatic neuroendocrine carcinoma","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of (68)Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.122.264207","article-title":"C-X-C motif chemokine receptor 4\u2013targeted radioligand therapy in patients with advanced T-cell lymphoma","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI15994","article-title":"Disruption of the CXCR4\/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide","volume":"111","year":"2003","journal-title":"J Clin Invest"},{"key":"bib33-20250621","first-page":"754","article-title":"Biokinetics and dosimetry of (177)Lu-pentixather","volume":"63","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:05:03Z","timestamp":1750532703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004674","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}